A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Insulet Corp (PODD) offers strong growth and profitability at a reasonable valuation. Its solid financial health makes it a top affordable growth stock.
Since May 2025, Insulet has been in a holding pattern, posting a small return of 3% while floating around $335.74. The stock also fell short of the S&P 500’s 11.9% gain during that period.
Discover how Insulet Corp (PODD) combines strong technical uptrends with high-growth fundamentals, presenting a potential market leader for growth investors.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 17.2% climb.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Thursday. Stay informed about the latest market trends.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 29.9% year on year to $706.3 million. On top of that, next quarter’s revenue guidance ($767.8 million at the midpoint) was surprisingly good and 5.1% above what analysts were expecting. Its non-GAAP profit of $1.24 per share was 8.1% above analysts’ consensus estimates.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting results this Thursday before market hours. Here’s what investors should know.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Discover how Louis Navellier's growth stock strategy identified Insulet Corp (PODD), a leader in innovative insulin delivery with strong earnings and sales growth.
